Suven Life Sciences on Thursday informed the exchanges that it has been granted one product patent from Brazil and one product patent from Eurasia corresponding to new chemical entities. The patent products are for the treatment of disorders associated with neurodegenerative diseases such as Alzheimer’s, attention deficient hyperactivity disorder (ADHD), Parkinson’s, Huntington’s disease, and schizophrenia, among others. The patents are valid through 2023 and 2034, respectively. Shares of Suven Life jumped 1.94 per cent at ₹226.15 on the BSE